Tag Archive for: biotech

iOnctura Announces Publication Of Pioneering Research Describing The Unique Biological Features Of Roginolisib

Preclinical Data On Roginolisib, An Oral First-In-Class Non-ATP Competitive Allosteric Modulator Of PI3Kδ, For The Potential Treatment Of Solid And Hematological Tumors Geneva, Switzerland and Amsterdam, The Netherlands, 16 March – iOnctura, a clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer, today announces the publication of non-clinical research on roginolisib in the […]

Positive phase 2 data from Atrial Fibrillation clinical trial – primary endpoint met

First-in-class SK channel inhibition proof of mechanism achieved First new approach to treating Atrial Fibrillation for 20 years Copenhagen, Denmark – Acesion Pharma (“Acesion”), the biotech pioneering first-in-class novel therapies for Atrial Fibrillation (“AF”), the most common cardiac arrhythmia, today announced positive data from its Phase 2 trial of AP30663, a first-in-class SK ion channel […]

Teitur Trophics Raises EUR 28M in Series A Financing to Advance the Development and Treatment for Neurodegenerative Diseases

Financing co-led by Sunstone Life Science Ventures and Sound Bioventures with participation from Industrifonden, Innovestor’s Life Science Fund and P53 Invest Discovery of a novel mechanism with the potential to prevent the death of neurons in neurodegenerative diseases First-in-Class, lead drug candidate advances into clinical development in a Phase 1b study Aarhus, Denmark March 14th, […]

Leucid Bio provides business update and outlook for 2023

Proprietary Lateral CAR Platform achieved pre-clinical proof-of-concept data demonstrating prolonged disease-free survival compared to other CAR T-cell products. Lead programme, LEU011 has completed pre-clinical development for the treatment of solid tumours and is in pre-clinical development for a range of haematological malignancies. Leucid expects to file its CTA to initiate the clinical trial in H1 […]

Ariceum Therapeutics Appoints Radioligand Expert, Germo Gericke, M.D., as Chief Medical Officer

Dr. Gericke brings extensive experience in the research and development of radioligand therapies Appointment coincides with launch of Ariceum International AG in Basel, Switzerland Berlin, Germany, 1 February 2023 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, is pleased to announce […]